Home › Liver Cancer (Hepatocellular Carcinoma)
Liver Cancer (Hepatocellular Carcinoma) clinical trials recruiting in the U.S.
131 studies for Liver Cancer (Hepatocellular Carcinoma) are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX31 studies
- New York City, NY24 studies
- Los Angeles, CA19 studies
- Dallas, TX19 studies
- Cleveland, OH18 studies
- Boston, MA18 studies
- Philadelphia, PA16 studies
- Chicago, IL16 studies
- Pittsburgh, PA15 studies
- Jacksonville, FL14 studies
- San Francisco, CA14 studies
- Orange, CA14 studies
- San Antonio, TX13 studies
- St. Louis, MO13 studies
- Rochester, MN12 studies
- Atlanta, GA11 studies
- Baltimore, MD11 studies
- Portland, OR11 studies
- Detroit, MI11 studies
- Nashville, TN10 studies
- Seattle, WA10 studies
- Washington, DC10 studies
- Mountain View, CA10 studies
- Baldwin Park, CA9 studies
- Ann Arbor, MI9 studies
- Arlington, VA9 studies
- Milwaukee, WI8 studies
- Durham, NC8 studies
- Birmingham, AL8 studies
- San Diego, CA8 studies
- Santa Monica, CA8 studies
- Miami, FL7 studies
- Phoenix, AZ7 studies
- Omaha, NE7 studies
- Tampa, FL7 studies
- Scottsdale, AZ7 studies
- New Haven, CT6 studies
- Tucson, AZ6 studies
- The Bronx, NY6 studies
- Aurora, CO6 studies
By state
- Alabama9 studies
- Arizona17 studies
- California54 studies
- Colorado11 studies
- Connecticut8 studies
- Delaware3 studies
- District of Columbia4 studies
- Florida27 studies
- Georgia12 studies
- Hawaii3 studies
- Illinois20 studies
- Indiana5 studies
- Iowa3 studies
- Kentucky6 studies
- Louisiana5 studies
- Maryland16 studies
- Massachusetts19 studies
- Michigan20 studies
- Minnesota21 studies
- Missouri14 studies
- Nebraska8 studies
- Nevada4 studies
- New Hampshire3 studies
- New Jersey10 studies
- New York33 studies
- North Carolina11 studies
- Ohio23 studies
- Oklahoma5 studies
- Oregon11 studies
- Pennsylvania27 studies
- Rhode Island3 studies
- South Carolina6 studies
- Tennessee14 studies
- Texas50 studies
- Utah5 studies
- Virginia17 studies
- Washington15 studies
- Wisconsin12 studies
Recently updated studies
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06265285A Phase 1 Study of the Safety and Tolerability of CTX-10726
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07227012National Liver Cancer Screening Trial
RecruitingPhase 4
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06084234Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06915753Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 23, 2026 · NCT07219459A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07291076A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Sep 22, 2026 · NCT06066138GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
RecruitingEarly phase 1
Ages 18 to 99 · All sexes · Updated Sep 18, 2026 · NCT07627191A Study Evaluating a New Radiation Treatment Workflow (NGDS)
Recruiting
Ages 21 and older · All sexes · Updated Sep 17, 2026 · NCT07824583A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06427941A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06007846Defining the Ablative Dose for Y-90 TARE
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07586046Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT04380545Evaluating Novel Therapies in ctDNA Positive GI Cancers
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05482516Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RecruitingObservational study
Ages 22 and older · All sexes · Updated Sep 11, 2026 · NCT06486454GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT04864054Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06526338Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06811116Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06921785THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07446257The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Sep 2, 2026 · NCT06995898From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.